Rather than relying on glucose metabolism as a tumor biomarker, recent studies provide evidence in support of specific immunoPET techniques that target overexpressed proteins such as CD8 and PD-L1, which are expressed in the TME and enhanced during IMT [28,29,30]. This evidence concerns the gene CD8A and neoplasm.